CD8A and metastatic neoplasm: Additionally, tumor-associated CD8 cell numbers were comparable between the peripheral and inner regions of primary tumors (Fig. 3g), but were further increased in primary and metastatic tumors relative to total tumor cells when LOXL2 inhibition or knockdown was combined with anti-PD-L1 (Fig. 3g and h, Supplementary Fig. 6b–e).